PATENT CLAIM ANALYSIS

Application Number: 16079059
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["514", "04400A"]

Abstract:
The present invention relates to methods of treating, preventing or managing intestinal fibrosis by inhibiting SMAD7. The invention is also directed to methods of monitoring effectiveness of treatment or management of intestinal fibrosis using a SMAD7 antisense oligonucleotide, as well as methods of regulating SMAD7 antisense oligonucleotide treatment, based on analysis of Transforming Growth Factor-β (TGF-β) levels, α-Smooth Muscle Actin (a-SMA) levels, and/or phosphorylated Mothers Against Decapentaplegic Homolog 3 (p-SMAD3) levels.

Claim (Index 93):
The method of  claim 76 ,  77 , or  80 , wherein the initial dose is less than 100 mg/day, less than 90 mg/day, less than 80 mg/day, less than 70 mg/day, less than 60 mg/day, less than 50 mg/day, less than 40 mg/day or less than 30 mg/day.

Metadata:
- Claim Count in Document: 51.0
- Percentile: 96.0
- Lexical Diversity: 1.55556
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15063077', '16046389', '12854558', '14144029', '12264058']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7755348906034891
- 35 USC 102 Novelty (BERT): 0.54055894893065
- Combined Prediction Score: 0.7520372964362052
- Mean Citation Score: 335.939554
- Max Citation Score: 336.40283
- Similarity Product: 141.27135869756012

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test